Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: a systematic review

[1]  Steve M. Taylor,et al.  Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. , 2015, The Journal of infectious diseases.

[2]  D. Kwiatkowski,et al.  K13-Propeller Polymorphisms in Plasmodium falciparum Parasites From Sub-Saharan Africa , 2014, The Journal of infectious diseases.

[3]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[4]  Steve M. Taylor,et al.  A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo. , 2014, The American journal of tropical medicine and hygiene.

[5]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[6]  P. Melin,et al.  Assessment of pfcrt 72-76 haplotypes eight years after chloroquine withdrawal in Kinshasa, Democratic Republic of Congo , 2013, Malaria Journal.

[7]  K. Lindblade,et al.  Importation of chloroquine-resistant Plasmodium falciparum by Guatemalan peacekeepers returning from the Democratic Republic of the Congo , 2013, Malaria Journal.

[8]  J. Perin,et al.  Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar , 2013, PloS one.

[9]  Steve M. Taylor,et al.  Plasmodium falciparum sulfadoxine resistance is geographically and genetically clustered within the DR Congo , 2013, Scientific Reports.

[10]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[11]  P. Rosenthal,et al.  Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene , 2010, Malaria Journal.

[12]  R. Hallett,et al.  Amodiaquine Resistance in Plasmodium falciparum Malaria in Afghanistan Is Associated with the pfcrt SVMNT Allele at Codons 72 to 76 , 2010, Antimicrobial Agents and Chemotherapy.

[13]  R. Durand,et al.  Association of microsatellite variations of Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) gene with reduced in vitro susceptibility to quinine: lack of confirmation in clinical isolates from Africa. , 2010, The American journal of tropical medicine and hygiene.

[14]  J. Peters,et al.  Role of pfmdr1 Amplification and Expression in Induction of Resistance to Artemisinin Derivatives in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.

[15]  P. Rosenthal,et al.  Resistance-mediating polymorphisms in Plasmodium falciparum infections in Kinshasa, Democratic Republic of the Congo. , 2009, The American journal of tropical medicine and hygiene.

[16]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[17]  S. Meshnick,et al.  dhfr and dhps genotype and sulfadoxine‐pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo , 2008, Tropical medicine & international health : TM & IH.

[18]  S. Krishna,et al.  The role of pfmdr1 in Plasmodium falciparum tolerance to artemether‐lumefantrine in Africa , 2007, Tropical medicine & international health : TM & IH.

[19]  C. Roper,et al.  Artesunate + amodiaquine and artesunate + sulphadoxine–pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine‐resistant haplotypes , 2006, Tropical medicine & international health : TM & IH.

[20]  D. Fidock,et al.  Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. , 2006, The Journal of infectious diseases.

[21]  D. Taramelli,et al.  Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa. , 2006, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[22]  T. Theander,et al.  Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. , 2006, The Journal of infectious diseases.

[23]  S. Vong,et al.  Assessing the efficacy of chloroquine and sulfadoxine–pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo , 2003, Tropical medicine & international health : TM & IH.

[24]  Y. Wataya,et al.  Analysis of Pfmdr 1 gene in mefloquine-resistant Plasmodium falciparum. , 2001, Nucleic acids research. Supplement.

[25]  T. Wellems,et al.  Chloroquine-resistant malaria. , 2001, The Journal of infectious diseases.

[26]  J. Wootton,et al.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. , 2000, Molecular cell.

[27]  J. E. Hyde,et al.  Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization , 1997, Molecular microbiology.

[28]  B. Bhandari,et al.  Chloroquine resistance in malaria. , 1994, Indian pediatrics.

[29]  T. Wellems,et al.  Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  U. d’Alessandro,et al.  MOLECULAR MARKERS ASSOCIATED WITH PLASMODIUM FALCIPARUM RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN THE DEMOCRATIC REPUBLIC OF CONGO , 2006 .

[31]  S. Meshnick,et al.  Prevalence of pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman assay. , 2005, Acta tropica.

[32]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[33]  Geneva,et al.  ANTIMALARIAL DRUG COMBINATION THERAPY Report of a WHO Technical Consultation , 2022 .